Results from the SOHO-01 trial supported expanded use of sevabertinib in adults with HER2-mutated, locally advanced or metastatic nonsquamous non–small cell lung cancer, including patients who had not...
In the replicate phase 3 OBERON and TITANIA trials, add-on tozorakimab 300 mg every 4 weeks significantly reduced annualized moderate or severe chronic obstructive pulmonary disease exacerbation rates...
A pooled analysis of two phase 3 ENHANCE trials evaluated whether the inhaled dual phosphodiesterase 3 and 4 inhibitor antifeminine reduces chronic obstructive pulmonary disease exacerbation frequency and...
A new national analysis provides clinicians with evidence on how chronic obstructive pulmonary disease affects post-discharge outcomes in adults with sickle cell disease hospitalized for acute chest...
A nationwide Belgian cohort study found that biologic therapy targeting interleukin (IL) 5 reduced moderate and severe exacerbations among adults with severe eosinophilic asthma, including those with...
Researchers in Graz, Austria, used machine learning and multiomics immune profiling to uncover a distinct chronic obstructive pulmonary disease subtype tied to emphysema severity and reduced gas exchange....
In a nationwide Danish trial of more than 130,000 adults aged 60 years and older, a single dose of the bivalent RSV prefusion F protein vaccine reduced all-cause cardiorespiratory hospitalizations by nearly...
